Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma.
Journal: Blood advances
Published: May 05, 2026
Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphoma.
Journal: British journal of haematology
Published: July 02, 2025
An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors.
Journal: ACS pharmacology & translational science
Published: June 10, 2025
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas.
Journal: British journal of haematology
Published: March 28, 2025
Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.
Journal: Leukemia & lymphoma
Published: February 03, 2025
Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 25, 2024
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
Journal: The New England journal of medicine
Published: June 20, 2024
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.
Journal: Blood advances
Published: March 17, 2023
Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial.
Journal: The Lancet. Haematology
Published: October 06, 2022
Last Updated: 09/26/2026